Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,061,007 | Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis In force · Medium confidence UsedRemaining | BioNTech AG | In force | Medium confidence | ||
| Application 12/420,612 | Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis Abandoned Abandoned Apr 6, 2013 | Ganymed Pharmaceuticals AG, a German Corporation and Johannes Gutenberg-Universitat Mainz | Abandoned | Abandoned Apr 6, 2013 |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Ganymed Pharmaceuticals AG.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.